Synairgen (LON:SNG) Share Price Passes Below Two Hundred Day Moving Average of $22.44
Synairgen (LON:SNG) Share Price Passes Below Two Hundred Day Moving Average of $22.44
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.Synairgen plc (LON:SNG – Get Rating)'s stock price crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of GBX 22.44 ($0.27) and traded as low as GBX 11 ($0.13). Synairgen shares last traded at GBX 12.50 ($0.15), with a volume of 990,485 shares.
在周五的交易中，Synairgen plc(伦敦股票代码：SNG-GET Rating)的股价跌破了200日移动均线。该股的200日移动均线为22.44英镑(0.27美元)，交易价格低至11英镑(0.13美元)。Synairgen的股票最新交易价格为12.50英镑(0.15美元)，成交量为990,485股。
Synairgen Stock Down 13.8 %
Synairgen股价下跌13.8%
The business's fifty day simple moving average is GBX 18.24 and its 200 day simple moving average is GBX 22.44. The stock has a market cap of £25.17 million and a price-to-earnings ratio of -0.51. The company has a current ratio of 6.35, a quick ratio of 6.35 and a debt-to-equity ratio of 0.09.
该业务的50日简单移动均线切入位为18.24,200日简单移动均线切入位为22.44。该股市值为2517万GB，市盈率为-0.51。该公司的流动比率为6.35，速动比率为6.35，债务权益比率为0.09。
Synairgen Company Profile
Synairgen公司简介
(Get Rating)
(获取评级)
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease.
Synairgen plc发现和开发治疗呼吸系统疾病的药物。该公司开发的产品有：治疗新冠肺炎的乙型吸入型干扰素SG001；治疗感冒和流感引起的哮喘的乙型干扰素吸入剂；治疗或预防慢性阻塞性肺病的乙型干扰素第二阶段临床试验；以及治疗特发性肺纤维化的LXL2抑制剂。
Read More
阅读更多内容
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- MarketBeat：回顾一周12/19-12/23
- 这些钢铁制造商理应在2023年观察名单上占有一席之地
- 通胀降温，标普500指数何去何从
- Cintas以经营杠杆击败通胀
- 你买下Palantir的决定可能只是个时间问题
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.
接受Synairgen Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Synairgen和相关公司的最新新闻和分析师评级的每日简明摘要。
